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Is echocardiographic epicardial 
adipose tissue thickness measurement 
a reliable and reproducible method 
for risk stratification?
To the Editor,
With great interest, we read the article titled “Epicardial adipose 
tissue thickness is associated with myocardial infarction and 
impaired coronary perfusion” published by Tanindi et al. (1) in Anatol 
J Cardiol 2015; 15: 224-31. It is a good paper with well-conducted 
analysis. Tanındı et al. (1) investigated the association between epi-
cardial adipose tissue thickness (EAT) and acute myocardial infarc-
tion (AMI) in their population. The measurement of EAT was per-
formed manually at end-systole on the free wall of the right ventricle 
perpendicular to the aortic annulus in standard parasternal long-axis 
view. Tanındı et al. (1) found a positive correlation between EAT and 
AMI. They highlighted that the echocardiographic measurement of 
EAT is a useful method for risk stratification and for choosing 
patients who need more aggressive treatment in terms of risk reduc-
tion. 
At present, the echocardiographic measurement of EAT, which 
reflects cardiac and visceral adiposity, has become one of the lead-
ing topics in cardiovascular imaging studies. EAT is suggested as a 
new cardiometabolic risk factor. Correlations between increased EAT 
and insulin resistance, metabolic syndrome, hypertension as well as 
cardiovascular diseases have been studied (2-4). The echocardio-
graphic measurement of EAT is a widely available, simple, safe, non-
invasive, cheap, and rapid method; however, it should be questioned 
whether EAT is a reliable and reproducible method. If it is not a reli-
able and reproducible method, then inaccurate measurements may 
affect our clinical decision and research results. In addition, EAT that 
was measured from the free wall of the right ventricle by echocar-
diography does not reflect all subepicardial adipose tissue volume. 
Saura et al. (5) investigated the reproducibility of the echocardio-
graphic measurement of EAT and compared the values with those 
obtained using multi-detector computed tomography (MDCT). 
Although the contrary was claimed, in a study by Saura et al. (5), they 
found a poor reproducibility of the echocardiographic measurements 
of EAT assessed by intraclass correlation coefficient. Moreover, mea-
surements with echocardiography and MDCT showed low concor-
dance. Saura et al. (5) found that echocardiography yielded larger 
values than those yielded by MDCT. In particular, there was a notable 
difference of up to 7 mm within two standard derivations of the mean 
values measured by these two different methods. The results of 
Saura et al. (5)’s study indicate that EAT measurements by echocar-
diography may lead to the misclassification of patients. Therefore, 
clinicians should be careful when this parameter is used as a diag-
nostic tool for risk stratification. 
Furthermore, there are some other controversial issues regarding 
EAT. There are no normality values of EAT, and the discussion on how 
to measure EAT by echocardiography is still ongoing. EAT may be 
deformed through the cardiac cycle, and to ensure the maximal sta-
bility of true EAT, it should be measured in end-diastole (5). Further 
comprehensive studies are required to investigate the reproducibility 
of EAT and to answer the other questions.
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Author`s Reply
To the Editor,
We thank the authors for their comments and interest in our study 
titled “Epicardial adipose tissue thickness is associated with myocar-
dial infarction and impaired coronary perfusion” (1) published in the 
Anatol J Cardiol 2015; 15: 224-31. In the last decade, many studies have 
highlighted an association between epicardial adipose tissue thickness 
(EAT) and coronary artery disease (CAD); thus, it has been proposed as 
a marker to detect cardiovascular risk. Of course, an ideal biomarker 
should reflect the degree of atherosclerosis, predict cardiovascular 
events, and indicate improvement after intervention. In addition, it 
would be further desirable if a biomarker could be easily and non-
invasively measured, and if the measurement was reproducible and 
standardized (2). 
As the authors mentioned, there has been a debate on the pre-
ferred method to measure EAT and on the range that should be consid-
ered as normal. Echocardiography is the method used to assess EAT by 
Iacobellis et al. (3) since 2003, and it is identified as the echo-free space 
between the outer wall of the myocardium and the visceral layer of the 
pericardium perpendicular to the free wall of the right ventricle at end-
systole. Although some investigators suggested that the measurement 
should be made at the end-diastole to coincide with other imaging 
modalities such as computed tomography (CT) and magnetic resonance 
imaging (MRI), many authors including Iacobellis et al. (3), the investiga-
tor who first presented echocardiographic EAT thickness to the litera-
ture, prefer to measure EAT at end-systole because EAT may be com-
pressed at end-diastole.
An important point is to set a clear and widely accepted reference 
range for a biomarker, as mentioned previously. Although EAT has been 
studied for more than a decade, there is no universally accepted cut-off 
point above which the EAT values can be definitely considered as 
abnormal. Many studies have provided cut-off values, but these studies 
have evaluated EAT from different points of view, such as its associa-
tion with atherosclerosis, subclinical atherosclerosis, presence of CAD, 
extent of CAD, and plaque morphology. Thus, there are many proposed 
EAT cut-off values in the literature. However, in the light of the current 
literature, EAT thickness of >5 mm is safely considered as abnormal (4).
Another important point in the evaluation of EAT is the method of 
choice. Echocardiography is easily available, inexpensive, and reproduc-
ible, as mentioned previously. CT and MRI have also been increasingly 
used to assess the amount of EAT, and they have high spatial resolution; 
their most important advantage is the possibility of volumetric assess-
ment. However, similar to echocardiography, there is no universally 
accepted cut-off value above which EAT is considered as abnormal (4). 
 The authors mentioned the study by Saura et al. (5) that reports a 
poor reproducibility and poor tomographic concordance for echocar-
diographic EAT measurement. However, it may not be appropriate to 
depend on a single study to conclude that echocardiography is not a 
reliable method. There are many other studies that report a good cor-
relation of echocardiographic EAT determination with CT and MRI (6).
The aim of our study was to show the association between EAT 
thickness, myocardial infarction, and coronary perfusion. We agree that 
EAT still has a long way to go before universally accepted ranges are 
set, and other criteria that are needed to establish a marker as a rou-
tinely used one are fulfilled. Nevertheless, we think that the findings of 
our study add to the current literature as we provide a cut-off value to 
predict AMI and poor coronary perfusion among patients with a clinical 
diagnosis of CAD.
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What is the real predictive value of 
red cell distribution width for the 
mortality in non-ST elevation acute 
coronary syndrome?
To the Editor,
I have read the recently published article by Bekler et al. (1) 
“Relationship between red cell distribution width and long-term mortality 
in patients with non-ST elevation acute coronary syndrome” entitled with 
great interest in Anatol J Cardiol 2014 Jun 23. In their study, authors 
reported that high red cell distribution width (RDW) level on admission is 
a predictor of long-term mortality in patients with non-ST elevation acute 
coronary syndrome (NST-ACS). In this paper, I would like to emphasize 
the possible effects of medical treatment of patient groups on the end-
points of this study. In the present study by Bekler et al. (1), there are no 
data regarding patient groups’ medications. It is well known that optimal 
medical therapy reduces the early and long-term mortality in patients 
with NST-ACS. Based on our previous knowledge and according to the 
current guideline, it is recommended to use oral beta-blockers, long-term 
treatment with aspirin, and dual antiplatelet therapy for at least 12 months 
as well as to use statins and angiotensin-converting enzyme inhibitors 
(ACEI)/angiotensin-receptor blockers (ARB) to reduce mortality and 
major adverse cardiovascular events (MACE) in NST-ACS patients (2). 
Also, it has been reported that dual antiplatelet therapy with ticagrelor 
significantly reduced the mortality and MACE in NST-ACS patients as 
opposed to the patients treated with aspirin and clopidogrel (3, 4). Hence, 
authors should comment on the incidence of patients treated with opti-
mal medical therapy in both high RDW and low RDW groups and compare 
the groups regarding beta-blockers, ACEI/ARB, statins, dual antiplatelet 
usage rates, and the type of dual antiplatelet therapy. Because the results 
of the present study by Bekler et al. (1) may not be due to high RDW level, 
less medications rates with optimal medical therapy in high RDW level 
group may be the main reason for higher mortality. 
In conclusion, the statistical data of the present study by Bekler et al. (1) 
may be improved. Authors should report the patients’ medications in both 
groups. High RDW level may indicate poor prognosis in NST-ACS patients. 
However, to define its exact role on mortality, conventional medical treat-
ments that are known to reduce the mortality should be considered.
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